Late at night, suddenly: the disciplinary commission has taken action again! A letter from a hospital stating the dismissal of four pharmaceutical representatives in the field of medicine and discipline inspection

Shandong Provincial Commission for Discipline Inspection and Supervision: Ensuring Effective Cooperation in the Concentrated Rectification of Corruption Issues in the Medical Industry

According to the website of the Shandong Provincial Commission for Discipline Inspection and Supervision, on August 7th, the Commission for Discipline Inspection and Supervision held a video conference to mobilize and deploy disciplinary inspection and supervision agencies to cooperate in the centralized rectification of corruption in the pharmaceutical industry throughout the province.

The meeting pointed out that in order to cooperate with the centralized rectification of corruption in the pharmaceutical industry, we need to tighten the responsibility chain, compact the main responsibility, effectively shoulder the supervision responsibility, promote the linkage of the "two responsibilities", and fully ensure the implementation of work. Adhere to strict crackdowns, comprehensively investigate problem clues, focus on highlighting key areas of investigation and punishment, severely crack down on bribery, accurately grasp policy strategies, and promote the formation of strong deterrence. Deepen the use of cases to promote reform, use cases as a warning, establish regulations and systems to block loopholes, advocate for the establishment of a new atmosphere and a positive atmosphere, and comprehensively promote long-term governance. Strengthen the implementation of responsibilities, strengthen organizational leadership, closely cooperate and cooperate, strictly enforce work discipline, and ensure effective cooperation in the centralized rectification of corruption issues in the pharmaceutical industry.

A hospital requires pharmaceutical companies to dismiss four pharmaceutical representatives

The recent anti-corruption storm in the pharmaceutical industry has been a bit fierce: representatives have been arrested again, academic conferences have been suspended, pharmaceutical groups have disbanded, and there are even rumors that a certain pharmaceutical company's office has been hacked

On the evening of the 7th, pictures circulated online showed that the Second Affiliated Hospital of the Naval Medical University had recently sent processing suggestion letters to Shanghai Novartis Trading Co., Ltd. and Beijing Novartis Pharmaceutical Co., Ltd. respectively. In the handling suggestion letter, it is stated that Changzheng Hospital, based on the "Reply to the Handling Opinions on Discovering Relevant Situations during Discipline Inspection Work," requires the two companies to respectively dismiss or transfer the pharmaceutical representatives involved, Xu Shengli, Meng Tingting, Chen Mengwei, and Li Xiaojuan, and provide feedback on the handling opinions to the hospital.

On the evening of August 7th, Novartis China announced that it had recently received a letter from a certain hospital, which involved two of our pharmaceutical representatives. Novartis attaches great importance to this incident. After verification by our company, one of the personnel mentioned in the letter has resigned from Novartis in 2018, and the other has not been hired by Novartis. Novartis always adheres to high ethical standards for compliant operations. In response to the situation reflected in this letter, our company is still conducting further investigation and communication.

Novartis is one of the world's largest pharmaceutical companies, headquartered in Basel, Switzerland, with products covering approximately 140 countries and regions worldwide.

In 2022, Novartis Group's net sales reached $50.5 billion, with innovative drug business accounting for 82% and non patented and biosimilar drug business accounting for 18%. In April 2022, Novartis announced the integration of Novartis Pharmaceuticals and Novartis Oncology into Novartis innovative drugs, further focusing on core treatment areas such as cardiovascular, immune, neuroscience, solid tumors, and hematological diseases, providing breakthrough innovative drugs for patients worldwide. Novartis plans to complete the 100% divestment and listing of Sanders business in the second half of 2023, thereby becoming a company completely focused on innovative drugs.

On July 24th, the First Affiliated Hospital of Sun Yat sen University issued the "2023 Special Campaign Plan for Correcting Unhealthy Practices in the Field of Pharmaceutical Purchasing and Sales and Medical Services"; The People's Hospital of Guangxi Zhuang Autonomous Region has recently released the "Implementation Plan for Deepening the Special Clearance of Unreasonable Remuneration", requiring all medical staff in the hospital to actively clear the unreasonable remuneration received from 2018 to May 2023, such as lecture fees, training fees, seminar fees, etc., with a focus on the issue of receiving "red envelopes" and kickbacks in various names and forms from medical devices, drugs, reagents and other production and operation enterprises or personnel in the process of cooperation and communication with enterprises.

There are also media reports that multiple hospitals in various provinces have held internal meetings, demanding that doctors refund their teaching fees. At the same time, different degrees of punishment will be imposed on pharmaceutical representatives who enter the hospital's diagnosis and treatment area without authorization to engage in illegal activities such as sales and prescription.

On July 28th, the disciplinary inspection and supervision organs cooperated in the mobilization and deployment video conference for the national centralized rectification of corruption in the pharmaceutical industry, pointing out that external supervision should be used to stimulate the internal driving force to fulfill the main responsibility, and to deepen the systematic governance of the pharmaceutical industry in all fields, all chains, and all coverage.

Currently, multiple pharmaceutical listed companies have responded to the relevant impact on interactive platforms.

Ma Yinglong stated that anti-corruption in the pharmaceutical industry helps promote healthy and high-quality development. The company always takes compliance as the bottom line and promotes sustainable and healthy business development.

Tai Chi Group replied that the company has been persistently promoting education on party conduct and clean governance. All units have organized cadres and employees to watch and learn from a series of anti-corruption warning films, using cases as a lesson, warning cadres and employees to strictly discipline themselves, continuously enhancing political, disciplinary, moral, and anti-corruption determination. In recent years, the company has regularly carried out family activities to promote the construction of clean families, strengthen the anti-corruption and integrity awareness of cadres and employee families, cultivate good family ethics, and establish a good corporate culture. The company operates and produces in compliance with regulations, and there have been no violations.

Zhongyao Holdings responded to investors by stating that as a state-owned listed company, the company has always adhered to law-abiding and compliant operations, and anti-corruption in the pharmaceutical industry will not have adverse effects on the company's operations. The company firmly supports the national efforts to carry out centralized rectification of corruption in the pharmaceutical industry. Concentrated rectification of corruption in the pharmaceutical industry is an important measure to promote the implementation of the Healthy China strategy, purify the pharmaceutical industry ecosystem, and safeguard the vital interests of the people. Medical anti-corruption is a necessary path for the industry to return to normal order, which is conducive to the long-term healthy development of the industry.

Beilu Pharmaceutical responded to investors by stating that rectifying corruption in the pharmaceutical industry is an inevitable requirement for promoting the implementation of the Healthy China strategy, purifying the pharmaceutical industry ecosystem, and safeguarding the vital interests of the people. The company will also actively respond to the national call and implement the spirit of anti-corruption.

US pharmaceutical stocks surged

Tonight's US stock market, the most beautiful stock is called Vistagen's pharmaceutical stock, which surged and circuit breaker! Established on May 26, 1998, it is a clinical biopharmaceutical company dedicated to developing a new generation of therapies for treating anxiety, depression, and certain other central nervous system diseases.

Why did it skyrocket? Because they have developed a drug, the Phase 3 PALISADE-2 trial of Fasedienol nasal spray in the treatment of social anxiety disorder has achieved positive initial results.

For the positive effect of this new drug PALISADE-2 phase III trial, Shawn Singh, CEO of the company, believes that this drug can change more than 250000 people suffering from social anxiety in the United States, and benefit millions of social anxiety people around the world. "As a new type of drug, our nasal spray pipeline has the potential to change the treatment pattern of many treatment fields."

According to the latest annual report of Vistagen, the company incurred a loss of $59.2477 million for the entire year of 2023, compared to a loss of $47.7624 million for the same period last year; The total revenue was only $227300, a year-on-year decrease of 120.5%.